soul trial oral semaglutide cardiovascular outcomes soul trial results π§Ώ is the first oral GLP-1 RA proven to reduce MACE in high-risk T2DM patients, extending protection beyond injectable formulations. Trial: Oral Semaglutide & Cardiovascular in T2DM SOUL (Semaglutide cardiOvascular oUtcomes triaL)
Pay in 4 interest-free payments of $7.30 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours Β· Estimated delivery Oct 26 - Oct 31










:max_bytes(150000):strip_icc()/are-night-sweats-a-symptom-of-cancer-514441-01-4a6b98d179c5404e89cc28d09e8928de.png)


















